These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 11025776)

  • 21. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
    Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
    Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical changes in prostate cancer after androgen deprivation therapy.
    Bostwick DG
    Mol Urol; 2000; 4(3):101-6;discussion 107. PubMed ID: 11062363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression.
    Ryan CJ; Smith A; Lal P; Satagopan J; Reuter V; Scardino P; Gerald W; Scher HI
    Urology; 2006 Oct; 68(4):834-9. PubMed ID: 17070363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
    Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
    J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
    Zhigang Z; Wenlv S
    Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
    Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
    J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model.
    Gabril MY; Onita T; Ji PG; Sakai H; Chan FL; Koropatnick J; Chin JL; Moussa M; Xuan JW
    Gene Ther; 2002 Dec; 9(23):1589-99. PubMed ID: 12424611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metallothionein expression in prostatic carcinoma: correlation with Gleason grade, pathologic stage, DNA content and serum level of prostate-specific antigen.
    Moussa M; Kloth D; Peers G; Cherian MG; Frei JV; Chin JL
    Clin Invest Med; 1997 Dec; 20(6):371-80. PubMed ID: 9413634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in free and free-to-total prostate specific antigen after androgen deprivation or chemotherapy in patients with advanced prostate cancer.
    Berruti A; Dogliotti L; Fasolis G; Mosca A; Tarabuzzi R; Torta M; Mari M; Fontana D; Angeli A
    J Urol; 1999 Jan; 161(1):176-81. PubMed ID: 10037393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
    Sheridan T; Herawi M; Epstein JI; Illei PB
    Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.
    Gleave ME; Goldenberg SL; Chin JL; Warner J; Saad F; Klotz LH; Jewett M; Kassabian V; Chetner M; Dupont C; Van Rensselaer S;
    J Urol; 2001 Aug; 166(2):500-6; discussion 506-7. PubMed ID: 11458055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors.
    Väisänen MR; Väisänen T; Jukkola-Vuorinen A; Vuopala KS; Desmond R; Selander KS; Vaarala MH
    Prostate; 2010 Jun; 70(8):817-24. PubMed ID: 20054821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen deprivation for minimal metastatic disease: threshold for achieving undetectable prostate-specific antigen.
    Beekman K; Morris M; Slovin S; Heller G; Wilton A; Bianco F; Scardino PT; Scher HI
    Urology; 2005 May; 65(5):947-52. PubMed ID: 15882729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
    Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
    BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer.
    Puccetti L; Supuran CT; Fasolo PP; Conti E; Sebastiani G; Lacquaniti S; Mandras R; Milazzo MG; Dogliani N; De Giuli P; Fasolis G
    Eur Urol; 2005 Aug; 48(2):215-21; Discussion 221-3. PubMed ID: 15992991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vascular endothelial growth factor expression in untreated and androgen-deprived patients with prostate cancer.
    Aslan G; Cimen S; Yorukoglu K; Tuna B; Sonmez D; Mungan U; Celebi I
    Pathol Res Pract; 2005; 201(8-9):593-8. PubMed ID: 16259113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR; Betancourt JE
    Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.